Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 5/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | APOB | P04114 | 2/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490270 | 0.89 | LMNA (0.45) | MTTPMCHR1PTGS1APOBTRPV1 | |
| SCHEMBL6493011 | 0.89 | MTTP (0.48) | MTTPMCHR1PTGS1APOBTRPV1 | |
| SCHEMBL6492769 | 0.88 | P2RX1 (0.50) | MCHR1PTGS1TRPV1SMO | |
| SCHEMBL6489566 | 0.88 | GCGR (0.43) | MTTPMCHR1PTGS1PDPK1APOB | |
| SCHEMBL6489909 | 0.87 | TAS1R3 (0.51) | MTTPAPOBTRPV1SMO | |
| SCHEMBL6491043 | 0.86 | PLG (0.46) | MTTPMCHR1APOBSMOPLG | |
| SCHEMBL7083682 | 0.86 | CA12 (0.45) | MCHR1PTGS1APOBTRPV1SMO | |
| SCHEMBL6791861 | 0.86 | PTGS1 (0.51) | MTTPPTGS1APOBTRPV1SMO | |
| SCHEMBL6503526 | 0.83 | TRPV1 (0.43) | MTTPMCHR1PTGS1APOBTRPV1 | |
| SCHEMBL6489810 | 0.82 | P2RX1 (0.50) | PTGS1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | MTTP 677/4885MCHR1 3592/4885PTGS1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.